Equities Analysts Offer Predictions for TSE:FRX Q3 Earnings

Fennec Pharmaceuticals Inc. (TSE:FRX) – Investment analysts at Wedbush raised their Q3 2025 earnings per share estimates for shares of Fennec Pharmaceuticals in a research report issued to clients and investors on Sunday, December 22nd. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings per share of $0.56 for the quarter, up from their prior forecast of $0.46. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ FY2026 earnings at $3.03 EPS and FY2027 earnings at $4.06 EPS.

Separately, Stephens upgraded shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th.

Fennec Pharmaceuticals Price Performance

FRX stock opened at C$8.93 on Tuesday. The business has a 50 day simple moving average of C$7.25 and a 200-day simple moving average of C$7.67. The company has a market capitalization of C$244.32 million, a P/E ratio of 89.30 and a beta of 0.25. Fennec Pharmaceuticals has a twelve month low of C$5.65 and a twelve month high of C$15.43. The company has a current ratio of 8.02, a quick ratio of 10.17 and a debt-to-equity ratio of 1,040.68.

Insider Transactions at Fennec Pharmaceuticals

In other news, Director Rostislav Christov Raykov purchased 25,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was purchased at an average cost of C$3.87 per share, with a total value of C$96,840.00. Also, Senior Officer Robert Christopher Andrade acquired 15,816 shares of the stock in a transaction on Monday, November 18th. The stock was acquired at an average cost of C$3.43 per share, for a total transaction of C$54,248.88. Over the last quarter, insiders acquired 41,612 shares of company stock worth $157,868. Company insiders own 16.20% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.